MAPK/Akt Signaling Pathways: Function, Regulation, Signaling, and Implications for Cancer Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 1729
Special Issue Editor
2. Endocrinology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Interests: pituitary tumors; adrenocortical carcinomas; medullary thyroid carcinomas; cell cytoskeleton; somatostatin receptors; dopamine receptor type 2; IGF2 system; RET
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
ERK/MAPK and PI3K/AKT pathways play a central role in regulating cell growth and proliferation, in response to extracellular and intracellular stimuli, both in physiological and pathological conditions. In particular, these signaling cascades are dysregulated in different human tumors. The multiple players involved in the regulation of ERK/MAPK and PI3K/AKT activity and their complex mechanisms of signal transduction in cancer cells have been only partially elucidated. Further studies shedding light on these mechanisms will contribute to identify new potential therapeutic targets and novel biomarkers predictive of tumor biological behavior.
In this Special Issue of Cancers, we will publish reviews and original research focusing on ERK/MAPK and PI3K/AKT pathways roles in mediating cancer cells growth, the molecular mechanisms of signal transduction involved, the genetic alterations affecting these pathways, and the therapeutic approaches that target ERK/MAPK and PI3K/AKT pathways.
Dr. Erika Peverelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ERK/MAPK pathway
- PI3K/AKT pathway
- human cancers
- therapeutic targets
- receptors
- cell proliferation
- genetic alterations
- biomarkers
- signal transduction
- growth factors receptors
- molecular mechanisms
- cell cycle progression
- apoptosis
- cell survival
- tumor biological behavior
